Cannabis Law Report

OCTOBER 5, 2021

will discuss the Company’s product pipeline with diversified indications for MYMD-1 as an immunometabolic regulator and Supera-CBD as a synthetic CBD derivative. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. Media: media@mymd.com. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

The Blunt Truth

AUGUST 13, 2019

CBD is “thriving” in the current regulatory environment, but is it doing so illegally? Food and Drug Administration (FDA) Commissioner Scott Gottlieb opined last week , “the CBD craze is getting out of hand. Current federal law expressly allows for the distribution of hemp-derived CBD products that contain 0.3% As former U.S.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

The Cannigma

JUNE 24, 2021

Countless people now use CBD and other hemp-derived products as part of a prescribed medical regimen, as a daily health supplement, or just a go-to panacea to make the stress of daily life a little bit easier to manage. That doesn’t mean that CBD or other cannabis products should be seen as a cure all on their own.

CBD 75

CBD Microdosing Edibles Sleep 75

Cannabis Law Report

JUNE 7, 2021

Supera-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. Media Contact: Will Johnson. blocking drugs, and aging and longevity. Investor Contact: Brett Maas. 646-536-7331.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

OCTOBER 17, 2019

(Tree of Knowledge) (CSE:TOKI) (OTC:TOKIF) expands global medical marijuana and CBD research in partnership with the Caribbean Institute of Pharmacy Policy (CIPPPAR) in Jamaica. Media Relations. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market. Natasha Raey. 1.778.552.4538.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

The Joint Blog

JULY 25, 2020

Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. CBD is everywhere these days. Do a quick Google search, and you’ll find thousands of websites selling CBD products online , as well as the locations of brick and mortar CBD stores near you.

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

JULY 8, 2021

NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. produced, THC-free 1 CBD products.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

JULY 7, 2021

Supera-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. Media Contact: Will Johnson. blocking drugs, and aging and longevity. Investor Contact: Robert Schatz. 646) 421-9523.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JULY 24, 2019

Food and Drug Administration sent a warning letter to the company for selling CBD-based products that claim to treat serious diseases. FDA has also determined that your “Bido CBD for Pets” products are unapproved new animal drugs that are unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). 355(a) and 331(d).

CBD 51

CBD Tincture Pets Chronic Pain 51

Cannabis Law Report

JANUARY 11, 2019

Questions continue to be raised, however, about the legality of one of the country’s most popular hemp products, hemp-derived cannabidiol (CBD). federal law protects the retail sale of hemp-derived CBD. . Our analysis follows: Hemp-derived CBD is no longer a controlled substance under federal law.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Cannabis Law Report

AUGUST 21, 2019

In November 2018, the legal status of cannabis was changed to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need, following a high-profile media campaign. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. E-commerce sales of CBD in the U.S. Consumers spent roughly $31.3

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Media Contact: Will Johnson. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

The Cannigma

JULY 1, 2022

What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible. The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

SEPTEMBER 24, 2019

Sativex is a cannabis-based medicine that contains THC and CBD and is licensed in the UK for people with multiple sclerosis. “CBD was not recommended by NICE for prescription on the NHS. Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with cannabis.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JULY 23, 2019

This is particularly the case for cannabis and cannabidiol (CBD) products. Thurston v Koi CBD, LLC. Koi CBD, LLC is a cannabis company based in California. Bianca Thurston, from Pennsylvania, purchased Koi’s CBD products in a local store. Marketing and Advertising Cannabis/CBD Products – Maryland Example.

Law 40

Law Clinical Trials CBD Edibles 40

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Media: Laura Radocaj. For more information, please visit www.virpaxpharma.com. About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.

Clinical Trials 52

Clinical Trials Treatment Research and Development Media 52

Cannabis Law Report

SEPTEMBER 29, 2021

Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. in Jerusalem, Israel) enhances the effectiveness and stability of CBD. Funding for this trial is from the National Institute on Drug Abuse (NIDA). “We

Clinical Trials 52

Clinical Trials Medicine Treatment Research and Development 52

Cannabis Law Report

JULY 8, 2021

“Our goal with this study is to enhance the existing treatment’s efficacy through adding CBD to create a new standard of care, potentially improving and extending glioblastoma patients’ quality of life.” Clomiphene will then be added to the regimen for up to 24 patients to rule out toxicity. SOURCE Enveric Biosciences.

Treatment 98

Treatment Clinical Trials CBD Patients 98

Otherside Farms

NOVEMBER 3, 2019

It’s interesting that something like CBD isolate should be enhanced given how much time and energy has been put into developing extraction techniques that even let us arrive at CBD isolate in the first place. But alas, one of the biggest criticisms of CBD isolate is that all it contains is CBD! What we don’t know.

Terpenes 58

Terpenes CBD Research and Development Cannabinoids 58

Cannabis Info

OCTOBER 11, 2019

The researchers are especially hoping the CBD-heavy strain will reduce the most deleterious and troubling effects of dementia. In the Australian clinical study, cannabinoids will be extracted and delivered in a mouth spray, making it easier to be administered to the elderly. Cannabis research in the U.S.

Treatment 45

Treatment Clinical Trials Cannabinoids Cannabis 45

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

CannaMD

MARCH 8, 2021

CBD treatment dose-dependently diminishes cocaine self-administration and moves the dose-response curve downward. Instead of restricting free speech, the FTC recommends parents practice “media literacy.”. Cesamet, like dronabinol-containing products, is indicated for nausea associated with cancer chemotherapy. How to learn more.

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

DECEMBER 28, 2021

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax has acquired the exclusive worldwide rights from Nanomerics to use its MET platform for the nasal delivery of CBD for the management of epilepsy in children (a rare pediatric disease) and adults.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

MARCH 29, 2020

According to Vividata’s National Cannabis Consumer Study , 70% of consumers are not sure they know the difference between THC and CBD. Others have faced the wrath of their consumers, media, and everyone in their supply chain networks for not complying with Health Canada’s standards and the Cannabis Act.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

NOVEMBER 10, 2021

Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults. Media: Laura Radocaj. For more information, please visit www.virpaxpharma.com. Forward-Looking Statement. Betsy Brod.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Puff Puff Post

SEPTEMBER 16, 2019

Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. This article analyses media representations of medicinal cannabis in Australian medical publications. Media framing of cannabis.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

FEBRUARY 28, 2020

The feeling of “we’re all going to get rich” soon began to permeate through almost every Bitcoin conference and event as mainstream media attention grew, and once the sheen came off and businesses began to pivot to blockchain, there was an air of desperation. We’re not all going to get rich. Perhaps we can rectify this in the Second Edition?

Law 59

Law Research and Development Recreational Cannabis 59

Puff Puff Post

SEPTEMBER 16, 2019

Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.

Programs 40

Programs Research and Development Education Treatment 40

The Cannigma

APRIL 8, 2021

If you have cancer, Michael, and you’re on chemotherapy, and you’re on 14 medicines that you got from your doctor, you sure as hell want to be talking to somebody who knows what’s going on when you say, “I’m going to start taking CBD, and I’m going to start doing this, that or the other.”. I’ll take this drug,” so we have to look back.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

DECEMBER 7, 2021

The four-week Institutional Review Board (IRB) approved randomized controlled trial (RCT) of nearly 3,000 participants assigned to different botanical products containing CBD revealed significant improvement across all five health outcomes studied: well-being, quality of life, longer-term pain, feelings of anxiety, and sleep quality.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

JUNE 4, 2021

Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. This list is focused on those who have had the largest impact for 2021. . Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51